Valgan (Valganciclovir) 450 mg

Indicated for:

• CMV Retinitis: Treatment in patients with Acquired Immunodeficiency Syndrome (AIDS).
• CMV Prophylaxis: Prevention of Cytomegalovirus disease in kidney, heart, and kidney-pancreas transplant recipients.

Strength: 450 mg tablet.

Standard Adult Regimens:

• Induction: 900 mg (2 tablets) twice daily for 21 days.
• Maintenance: 900 mg (2 tablets) once daily.

⚠️ Administration: Must be taken WITH FOOD to ensure maximum absorption. Do not break or crush tablets (potential teratogen/carcinogen hazard).

• Hypersensitivity to valganciclovir, ganciclovir, or acyclovir.
• Severe bone marrow depression (Neutrophils < 500, Platelets < 25,000).
• Pregnancy and breastfeeding (FDA Category X).

Warning: Men should use barrier contraception during and for 90 days post-treatment.

Strict monitoring is required:

• Hematologic Toxicity: Severe neutropenia, anemia, and thrombocytopenia. Frequent Complete Blood Counts (CBC) are mandatory.
• Gastrointestinal: Diarrhea is the most common side effect. Nausea and vomiting may occur.
• Fever and fatigue.